Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks

Postgraduate Medicine

Volumn 128, Issue 4, 2016, Pages 371-380

  Blonde, Lawrence ^a   Stenlöf, Kaj ^b   Fung, Albert ^c   Xie, John ^c   Canovatchel, William ^c   Meininger, Gary ^c  

^a OCHSNER MEDICAL CENTER   (United States)

^b National Office for Clinical Studies   (Sweden)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Body composition; body weight; canagliflozin; sodium glucose co transporter 2 (SGLT2) inhibitor; type 2 diabetes mellitus; weight loss

Indexed keywords

CANAGLIFLOZIN; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; BONE DENSITOMETRY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME FACTOR;

ADIPOSITY; AGED; BODY COMPOSITION; BODY MASS INDEX; BODY WEIGHT; CANAGLIFLOZIN; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS; TIME FACTORS; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 84978388879     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2016.1169894     Document Type: Article

References (45)

1. L.Van Gaal, A.Scheen Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38:1161–1172.
2. S.E.Inzucchi, R.M.Bergenstal, J.B.Buse, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
3. A.Goyal, K.R.Nimmakayala, J.Zonszein. Is there a paradox in obesity? Cardiol Rev. 2014;22:163–170.
4. A.Gastaldelli. Abdominal fat: does it predict the development of type 2 diabetes? Am J Clin Nutr. 2008;87:1118–1119.
5. R.R.Wing, W.Lang, T.A.Wadden, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481–1486.
6. M.D.Jensen, D.H.Ryan, C.M.Apovian, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129:S102–S138.
7. S.F.Noria, T.Grantcharov. Biological effects of bariatric surgery on obesity-related comorbidities. Can J Surg. 2013;56:47–57.
8. S.B.Traina, A.Slee, S.Woo, et al. The importance of weight change experiences for performance of diabetes self-care: a patient-centered approach to evaluating clinical outcomes in type 2 diabetes. Diabetes Ther. 2015;6:611–625.
9. K.Stenlöf, W.T.Cefalu, K.A.Kim, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–382.
10. F.J.Lavalle-González, A.Januszewicz, J.Davidson, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–2592.
11. J.P.Wilding, G.Charpentier, P.Hollander, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67:1267–1282.
12. T.Forst, R.Guthrie, R.Goldenberg, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16:467–477.
13. K.Stenlöf, W.T.Cefalu, K.A.Kim, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30:163–175.
14. W.T.Cefalu, L.A.Leiter, K.H.Yoon, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–950.
15. B.Bode, K.Stenlöf, D.Sullivan, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract. 2013;41:72–84.
16. L.A.Leiter, K.H.Yoon, P.Arias, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38:355–364.
17. B.Bode, K.Stenlöf, S.Harris, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17:294–303.
18. G.Schernthaner, J.L.Gross, J.Rosenstock, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care. 2013;36:2508–2515.
19. J.F.Yale, G.Bakris, B.Cariou, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–473.
20. J.F.Yale, G.Bakris, B.Cariou, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16:1016–1027.
21. B.Neal, V.Perkovic, D.De Zeeuw, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38:403–411.
22. G.Fulcher, D.R.Matthews, V.Perkovic, et al. Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial. Diabetes Ther. 2015;6:289–302.
23. S.Traina, R.Guthrie, A.Slee. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgrad Med. 2014;126:7–15.
24. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res. 1998;6:51S–209S.
25. J.P.Bilezikian, N.B.Watts, K.Usiskin, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. J Clin Endocrinol Metab. 2016;101:44–51.
26. J.M.Miles, L.Leiter, P.Hollander, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25:1123–1128.
27. P.M.O’Neil, S.R.Smith, N.J.Weissman, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20:1426–1436.
28. X.Pi-Sunyer, G.Blackburn, F.L.Brancati, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care. 2007;30:1374–1383.
29. K.M.Gadde, D.B.Allison, D.H.Ryan, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–1352.
30. D.B.Allison, K.M.Gadde, W.T.Garvey, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330–342.
31. K.H.Jensen. Incretin-based therapy for type 2 diabetes: overcoming unmet needs. Med Update. 2010;20:105–112.
32. L.Blonde, R.Pencek, L.MacConell. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:12.
33. H.J.Pownall, G.A.Bray, L.E.Wagenknecht, et al. Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: the Look AHEAD study. Obesity (Silver Spring). 2015;23:565–572.
34. J.Jendle, M.A.Nauck, D.R.Matthews, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11:1163–1172.
35. S.Sha, D.Polidori, T.Heise, et al. Effect of the sodium glucose co-transporter 2 inhibitor, canagliflozin, on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:1087–1095.
36. J.Rosenstock, N.Aggarwal, D.Polidori, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232–1238.
37. D.Devineni, C.R.Curtin, D.Polidori, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013;53:601–610.
38. S.Sha, D.Devineni, A.Ghosh, et al. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One. 2014;9:e105638.
39. K.D.Hall, G.Sacks, D.Chandramohan, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet. 2011;378:826–837.
40. C.J.Bailey, J.L.Gross, D.Hennicken, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.
41. M.Ridderstrale, K.R.Andersen, C.Zeller, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691–700.
42. D.Devineni, L.Morrow, M.Hompesch, et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14:539–545.
43. E.Ferrannini, E.Muscelli, S.Frascerra, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508.
44. D.Z.Cherney, B.A.Perkins, N.Soleymanlou, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–597.
45. 1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58:1183–1187.